Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Docetaxel in 2nd Line Advanced Non-Squamous NSCLC
NCT03646968Phase 2Recruiting
- Sponsor
- Yongchang Zhang
- Start
- Aug 2018
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Yongchang Zhang. Primary endpoint: Objective Response Rate at 1 year. Started Aug 2018; status: recruiting.
02
Drugs
anlotinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03646968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03646968.